Updated on 3 February 2014
Step 3: The Department of Biotechnology (DBT), Government of India, and other multinational companies operating in Bangalore should pitch in with funds to help run this as a national facility.
Similar things have happened abroad in the recent past. AstraZeneca itself has done this in Montreal city in Quebec, Canada, in 2012. AstraZeneca closed its neuroscience research center in Montreal in February 2012 that employed 130 scientists. However, the Quebec government salvaged it by forming a cooperative venture called NeoMed Institute, supported by the state and the Canadian government.
AstraZenca gifted the facility to Quebec and also provided $ 5 million. Pfizer, which has operations in Quebec, put in another $3.5 million. Furthermore, the governments and other agencies arranged over $100 million. By December 2012, the new center had started functioning as an incubator.
Similarly, Merck Sharp & Dohme "gifted" its $150 million (Rs 900 crore) advanced research center near Glasgow, Scotland, when it decided to close it in February 2012. The facility was taken over by BioCity Scotland, a joint venture between BioCity Nottingham and Roslin BioCenter, both biotech incubators, under the guidance of Scottish government. Today BioCity Scotland is a thriving biopark housing dozens of biotech companies.
If there is a will, there is a way, for the Karnataka government to restore a research center, which is part of Bangalore's and Karnataka's rich scientific heritage. The ball is in the court of the Karnataka chief minister Mr Siddaramaiah.